Emily K. Mader

TL;DR: MSC should be used as carriers of MV for intraperitoneal virotherapy in measles-immune ovarian cancer patients if MV-infected mesenchymal stem cell (MSC) carriers are used.

TL;DR: The feasibility of using patient derived MSC as carriers for oncolytic MV therapy is confirmed and an approach where MSC from ovarian cancer patients will be expanded, frozen and validated to ensure compliance with the release criteria is proposed.

TL;DR: It is concluded that the CPA regimen of four daily doses at 370 mg m–2 should be evaluated clinically with i.v. virotherapy to control the antiviral antibody response and facilitate effective repeat dosing.

TL;DR: A cautious approach to dose escalation is proposed in a phase I clinical trial among patients with HCC using VSV-hIFNbeta injected into the left hepatic lobe under computed tomographic guidance.

TL;DR: The hybrid VSV/MV lacks neurotoxicity, replicates rapidly with VSV kinetics, and selectively targets CD46 on tumor cells, and its in vivo performance in a myeloma xenograft model was substantially superior to either MV or widely used recombinant oncolytic VSV-M51.